Tasigna 150mg (Nilotinib) capsules
Apple pharmaceuticals
description
Tasigna 150mg is cancer drugs, the main ingredient which is used as lapatinib, which prohibits growth of the tumor cells. Nilotinib is sold under the brand name Tasigna which is a targeted cancer medication Tasigna tablet belongs to the class of kinase inhibitors. The medicine Tasigna in children younger than 1 year has Tasigna 150mg capsules no safety and efficacy not been established The drug Tasigna is a prescription drugs, which is used under the knowledge of medical oncologist.
DOSAGE
The usual dose of Tasigna Tablet should be given as twice daily at 12 hours time intervals Tasigna must be administer on an empty stomach Taking of food should not be at least 1 hour after the dose is taken or 2 hours before the dose is taken Who are unable to taken the Tasigna capsules, the patients can be dispersed the tablet in one teaspoon of applesauce. This tablet should be administer immediately within 15 minutes Tasigna 150mg should be combination with hematopoietic growth factors such as erythropoietin or G-CSF Also concomitant use with hydroxyurea or anagrelide
Dosage in adult patients with Philadelphia positive CML-CP :
The regular dose of the Tasigna 150mg tablet in this condition given is 300mg should be given orally as twice daily.
With resistant or intolerant Philadelphia positive CML-CP and CML-AP:
The normal dose is 400mg should be administered as orally twice in a day.
In pediatrics:
The normal dose 230mg/m2 should be administer orally twice daily The maximum dose of Tablet Tasigna is 400mg.
PHARMACOKINETICS
Absorption:
The Tasigna 150mg has bioavailability about 50% The time of peak plasma concentration is occurred within 3 hours after administration.
Distribution:
The Tasigna 150mg capsules has serum protein binding is approximately 98% The Nilotinib blood to serum ratio is 0.68
Metabolism:
Tasigna is metabolized via CYP3A4 mediated oxidation. The prime flowing component in the blood stream is Nilotinib.
Elimination:
The half life period of Tasigna 150mg Tablet is approximately 17 hours. The mean apparent clearance value is 29L/hr.
Effect of food:
The effect of drug is increased to 82% when the dose was given 30 minutes after a high fat meal when compared to fasted patient.
The Tasigna 150mg has bioavailability about 50% The time of peak plasma concentration is occurred within 3 hours after administration.
Distribution:
The Tasigna 150mg capsules has serum protein binding is approximately 98% The Nilotinib blood to serum ratio is 0.68
Metabolism:
Tasigna is metabolized via CYP3A4 mediated oxidation. The prime flowing component in the blood stream is Nilotinib.
Elimination:
The half life period of Tasigna 150mg Tablet is approximately 17 hours. The mean apparent clearance value is 29L/hr.
Effect of food:
The effect of drug is increased to 82% when the dose was given 30 minutes after a high fat meal when compared to fasted patient.
MECHANISM OF ACTION
CML: chronic myelogenous leukemia is caused by BCR-ABL oncogene.Tasigna (Nilotinib mechanism of action ) is a kinase inhibitor, which prohibits BCR-ABL kinase activity. Binding of Tasigna 150mg capsules to the ATP-binding site of BCR-ABL protein. The drug Tasigna prevents the proliferation of murine leukemic cell lines and human cell lines derived from patients with Philadelphia positive CML
PRECAUTIONS
Tasigna 150mg may cause thrombocytopenia, neutropenia and anemia, so check blood counts periodically to reduce these complications
Embryo fetal damage:
While using this in pregnancy then the drug Tasigna causes fetal damage Examine the patients properly who are stop the Tasigna therapy, the range of Bcr-Abl transcripts level. Use the drug with caution while using Tasigna in patient who are suffered with Hypokalemia Hypomagnesemia Hepatotoxicity Electrolyte abnormalities
Long QT syndrome :
Monitor ECG frequently Avoid concomitant use of Tasigna with anti-arrhythmia agents Provide supportive measures
Pancreatitis and elevated lipase :
Patient suffering with pancreatitis may have serum lipase levels increase, this may results in abdominal symptoms and to decrease the problems, treatment should be postponed & undergone with appropriate diagnostics. Test serum lipase value periodically.
Tumor lysis syndrome:
Maintain with sufficient hydration Balance the level of uric acid before starting the treatment.
Embryo fetal damage:
While using this in pregnancy then the drug Tasigna causes fetal damage Examine the patients properly who are stop the Tasigna therapy, the range of Bcr-Abl transcripts level. Use the drug with caution while using Tasigna in patient who are suffered with Hypokalemia Hypomagnesemia Hepatotoxicity Electrolyte abnormalities
Long QT syndrome :
Monitor ECG frequently Avoid concomitant use of Tasigna with anti-arrhythmia agents Provide supportive measures
Pancreatitis and elevated lipase :
Patient suffering with pancreatitis may have serum lipase levels increase, this may results in abdominal symptoms and to decrease the problems, treatment should be postponed & undergone with appropriate diagnostics. Test serum lipase value periodically.
Tumor lysis syndrome:
Maintain with sufficient hydration Balance the level of uric acid before starting the treatment.
DRUG INTERACTION
While interaction of strong CYP3A inhibitors with tasigna drug interactions leads to increase nilotinib concentrations compared to while using Tasigna alone Concomitant use with strong CYP3A inducer leads to reduce nilotinib concentration Tasigna interaction With proton pump inhibitors: decrease the Tasigna 150mg efficacy Avoid combination of Tasigna with drugs that may prolong the QT interval like anti-arrhythmic drugs.
CONTRAINDICATION
Tasigna tablet is contraindicated in the patients who are having; Hypokalemia Hypomagnesemia Long QT syndrome
MISSED DOSE
If patients missed to have the dose , then administer the dose of Tasigna 150mg should be take within the time, or the missed dose should be swapped and continue the next dosing schedule. Consult with your doctor for more clarification
STORAGE
Stored at between 68℉ to 77℉ (20℃ to 25℃) Tasigna 150mg capsules room temperature keep away from heat, moisture and light.
SIDE EFFECTS
General: Fatigue, pyrexia, asthenia, peripheral edema, face edema
Pulmonary: Dyspnae , Cough, oropharyngeal pain,
Skin: Rash, Pruritus, alopecia, dry skin
GIT: Nausea, constipation, diarrhea, vomiting, upper abdominal pain, dyspepsia
Nerve system: Dizziness , Headache,
Vascular: Hypertension
Muscle: Myalgia, arthralgia, muscle spasm, pain in extremity, back pain
Infections & infestations: Nasopharyngitis, upper respiratory tract infection, influenza, gastroenteritis
Eye: Eyelid edema, periorbital edema
Psychiatric: Insomnia , this are the tasigna side effects.
Pulmonary: Dyspnae , Cough, oropharyngeal pain,
Skin: Rash, Pruritus, alopecia, dry skin
GIT: Nausea, constipation, diarrhea, vomiting, upper abdominal pain, dyspepsia
Nerve system: Dizziness , Headache,
Vascular: Hypertension
Muscle: Myalgia, arthralgia, muscle spasm, pain in extremity, back pain
Infections & infestations: Nasopharyngitis, upper respiratory tract infection, influenza, gastroenteritis
Eye: Eyelid edema, periorbital edema
Psychiatric: Insomnia , this are the tasigna side effects.
Comments
Post a Comment